- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03064269
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
November 27, 2023 updated by: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sheng-Li Xue, MD
- Phone Number: 86-13328008851
- Email: slxue@suda.edu.cn
Study Contact Backup
- Name: Lei Yu, Ph.D
- Phone Number: 86-13818629089
- Email: ylyh188@163.com
Study Locations
-
-
-
Suzhou, China
- Recruiting
- The First Affiliated Hospital of Soochow University
-
Contact:
- Sheng-Li Xue, Ph.D
- Phone Number: 86-13328008851
- Email: slxue@suda.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 60 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with CD19 positive central nervous system B-cell acute lymphocytic leukemia
- ALT/ AST 《 3x normal
- Creatinine 《 3x normal
- Age:10-60.
- Signed informed consent
Exclusion Criteria:
- Active hepatitis B , hepatitis C or HIV infection
- Uncontrolled active infection
- Pregnancy or breast-feeding women
- Survival less than four weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
|
CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The complete remission (CR) rate
Time Frame: Participants will be followed for the duration of the treatment, an expected average of 12 months
|
The safety of the humanized CD19 CAR-T cells treatment will be evalated and the maximum tolerated dose will be determined
|
Participants will be followed for the duration of the treatment, an expected average of 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sheng-Li Xue, Ph.D, The First Affiliated Hospital of Soochow University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2017
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
February 18, 2017
First Submitted That Met QC Criteria
February 21, 2017
First Posted (Actual)
February 27, 2017
Study Record Updates
Last Update Posted (Actual)
November 29, 2023
Last Update Submitted That Met QC Criteria
November 27, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UnicarTherapy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B-cell Acute Lymphocytic Leukemia
-
First Affiliated Hospital of Wenzhou Medical UniversitySecond Affiliated Hospital of Nanchang University; Hrain Biotechnology Co.,...UnknownHematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | B-cell Adult Acute Lymphoblastic LeukemiaChina
-
National Cancer Institute (NCI)RecruitingLymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALLUnited States
-
National Cancer Institute (NCI)RecruitingLymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin LymphomaUnited States
-
Shenzhen Second People's HospitalUnknownLymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, Lymphocytic, Acute, B-CellChina
-
University College, LondonRecruiting
-
Sumithira VasuRecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditionsUnited States
-
Hospital Israelita Albert EinsteinMiltenyi Biotec, Inc.Not yet recruitingAcute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory | Acute Lymphoblastic Leukemia RefractoryBrazil
-
Shanxi Province Cancer HospitalShanghai Ultra-T Immune Therapeutics Co. LTDRecruitingAcute Lymphocytic Leukemia, B-CellChina
-
Miltenyi Biomedicine GmbHRecruitingB-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia RefractoryGermany
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
Clinical Trials on CD19 CAR-T cells
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAcute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B CellChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
Miltenyi Biomedicine GmbHRecruitingB-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia RefractoryGermany
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.Recruiting
-
Miltenyi Biomedicine GmbHNot yet recruiting
-
Sheba Medical CenterUnknownAcute Lymphoblastic Leukemia, B-precursor | Non-Hodgkin Lymphoma, B-cellIsrael
-
Institute of Hematology & Blood Diseases HospitalJuventas Cell Therapy Ltd.; Union Stem cell & gene engineering Co.LTDCompletedAcute Lymphoblastic Leukemia, Adult B-Cell | Acute Lymphoblastic Leukaemia RecurrentChina